Alaa Abuawad

Alaa Abuawad

Auto-generated profile, based on publicly available information

Alaa Abuawad

Faculty of Pharmacy, Applied Science Private University, Amman 11937, Jordan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
AAAreen Alshweiat
Areen Alshweiat
MJMai Jaber
Mai Jaber
AAAlaa Abuawad
Alaa Abuawad
TATamara Athamneh
Tamara Athamneh
MOMuna Oqal
Muna Oqal

22 December 2025 in Exploration of Medicine
Verified
Journal Article
Open access
PDF file
AAAseel Abu Awad
Aseel Abu Awad
KHKhawla Abu Hammour
Khawla Abu Hammour
AAAlaa Abuawad
Alaa Abuawad
MZMohammed Zawiah
Mohammed Zawiah
RFRana Abu Farha
Rana Abu Farha
Aim: Community-acquired pneumonia (CAP) is a leading cause of global morbidity and mortality, and it is often treated with fluoroquinolone antibiotics. Misuse of fluoroquinolones is a known driver of antimicrobial resistance, and de-escalation of antibiotics is not only effective for patient outcomes but also reduces resistance. The aim of this study was to assess the association of fluoroquinolone de-escalation with length of stay (LOS), mortality, and other microbiological culture results in hospitalized adults with CAP. Methods: A retrospective cohort investigation took place with adult patients suspected of CAP in a tertiary care center in Jordan. The study examined outcomes for fluoroquinolone de-escalation that included hospital LOS, mortality, and examined the relationship between the results of microbial cultures and the outcome of de-escalation. Results: The study sample consisted of 125 patients with a median age of 73 years [interquartile range (IQR) = 24]. Around 65% (n = 81) of the patients were male, and 35% (n = 44) were female. The fluoroquinolone therapy was mostly levofloxacin (99.2%, n = 124). Fluoroquinolone de-escalation was medically justified in 32.8% (n = 41) of patients. When comparing the rate of successful de-escalation between those with positive and negative cultures (after the exclusion of 3 patients), positive cultures were statistically more likely to de-escalate than negative cultures, 61.5% (16/26) to 26.0% (25/96) (p = 0.002). Patients in the successful de-escalation had a statistically shorter length of hospital stay; 12 days (IQR = 8) against the failed/inappropriate group, 18 days (IQR = 11) (p = 0.004). There was no significant difference in mortality; 70.1% (n = 29) survived in the de-escalated group and 76.5% (n = 62) in the failed/inappropriate group (p = 0.514). Conclusions: In CAP, fluoroquinolone de-escalation may result in shorter hospital stays but does not alter mortality rates. However, limitations in establishing appropriateness for de-escalation imply the need for further studies to validate the findings.